Chronic obstructive pulmonary disease (COPD) Respiratory
Conditions
Interventions
Those patients who are diagnosed with COPD and cared for by participating general practitioners will be included, provided that they fulfil the inclusion criteria. The healthcare professionals will id
if the last test was more than 6 months ago, a new spirometry test will have to be taken. A forced spirometry test is required, for which the recommendations of the Spanish Society for Pneumology and
Sponsors
Instituto de Salud Carlos III (Spain)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 20/01/2016: Setting: Primary Care Centres in Teis, Matamá, Pazos de Borbén and Sárdoma in the Vigo Health Authority (Pontevedra, Galicia), and Son Pisà, Escola Graduada and Coll dén Rebassa in the Balearic Islands Health Authority (Balearic Islands). Through these centres, doctors/nurses potentially willing to participate were identified (using the ‘snowball’ method) both in Spain (Aragón, Catalonia, Canary Islands) and other European countries (Bulgaria, Croatia, Germany, Macedonia, Romania and Slovenia, in Europe). Subjects: Patients diagnosed with COPD. Inclusion criteria: 1. Patients with an obstruction, defined by a FEV1 lower than 80% of the expected post-bronchodilator FEV in the presence of a FEV1 quotient/forced vital capacity (FVC) lower than 70%. 2. Patients in a stable phase of COPD, clinically defined as at least 6 weeks since the last exacerbation 3. Acceptance to participate in the study by providing written informed consent Previous inclusion criteria: Setting: Primary Care Centres in Teis, Matamá, Pazos de Borbén and Sárdoma in the Vigo Health Authority (Pontevedra, Galicia), and Son Pisà, Escola Graduada and Coll dén Rebassa in the Balearic Islands Health Authority (Balearic Islands). Through these centres, doctors/nurses potentially willing to participate will be identified (using the ‘snowball’ method) both in Spain and other European countries to be confirmed. Subsequently, they will be invited and informed by e-mail about the description of the background and objectives of the study, as well as the implications of their participation. Subjects: Patients diagnosed with COPD. Inclusion criteria: 1. Patients with an obstruction, defined by a FEV1 lower than 80% of the expected post-bronchodilator FEV in the presence of a FEV1 quotient/forced vital capacity (FVC) lower than 70%. 2. Patients in a stable phase of COPD, clinically defined as at least 6 weeks since the last exacerbation 3. Acceptance to participate in the study by providing written informed consent
Exclusion criteria
Exclusion criteria: COPD patients. Exclusion criteria: 1. Patients diagnosed with cystic fibrosis, or bronchiectasis of a different origin to COPD (tuberculosis, childhood infections, immunodeficiencies, and severe cognitive or mobility impairment). 2. Patients diagnosed with a severe chronic disease, besides COPD (active malignancy, AIDS, heart failure, severe kidney or liver failure, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival without exacerbations will be assessed after 3, 4 and 5 years. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mortality from all causes and those specifically due to respiratory causes (secondary) | — |
Countries
Bulgaria, Croatia, Germany, Macedonia, Romania, Slovenia, Spain
Outcome results
None listed